Clinical Report: Strengthen your PD-L1 expertise
Background
PD-L1 expression is a critical biomarker in oncology, influencing treatment decisions for various cancers, including gastric and esophageal adenocarcinomas. The complexity of PD-L1 scoring necessitates ongoing education and training for pathologists to reduce variability in assessments.
Data Highlights
No numerical data provided in the source material.
Key Findings
- Training sessions for pathologists can significantly improve inter- and intra-reader agreement in PD-L1 scoring.
- The Combined Positive Score (CPS) is the preferred method for PD-L1 evaluation in gastric and GEJ cancers.
- Recent guidelines emphasize the prognostic value of CPS over other scoring systems in gastroesophageal cancers.
- Biomarker-driven testing can inform treatment decisions and support optimal patient management.
- Real-world case reviews can enhance confidence in CPS evaluation among pathologists.
Clinical Implications
Pathologists should engage in specialized training to improve their skills in PD-L1 evaluation, particularly in the context of CPS.
Conclusion
Enhancing PD-L1 expertise through training and real-world case evaluations is vital for pathologists.
Related Resources & Content
- British Journal of Biomedical Science, 2026 -- Training on PD-L1 scoring in non-small cell lung cancer with high intra- and inter-reader agreement: results of a worldwide microscopic/digital image-based training of 751 pathologists
- Blood Cancer Journal, 2014 -- The stimulation of PD-L1-specific cytotoxic T lymphocytes can both directly and indirectly enhance antileukemic immunity
- the pathologist, 2026 -- Pathologist Perspectives on PD-L1 CPS Scoring in Challenging Cases.
- Frontiers in Immunology, 2026 -- Multi-omics biomarkers for predicting resistance, hyperprogression, and immune-related toxicity during PD-1/PD-L1 therapy in lung cancer: a literature review
- Premarket Approval (PMA) -- FDA document on PD-L1 IHC 22C3 pharmDx
- Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update | Journal of Clinical Oncology, 2026
- FDA - PD-L1 IHC 22C3 pharmDx Companion Diagnostic
- ASCO Guideline Update for Advanced Gastroesophageal Cancer
- A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048) - NCI
Based on findings from:
Strengthen your PD-L1 expertise
The Pathologist, 2026.
https://thepathologist.com/webinars/2026/strengthen-your-pd-l1-expertise/
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
